Saliogen Therapeutics Inc. has nominated a development candidate, SGT-1001, for the treatment of Stargardt disease. SGT-1001 is being developed as a one-time, nonviral therapy to slow or stop the progressive loss of central vision in people with Stargardt disease, regardless of the type of mutation.
Inmed Pharmaceuticals Inc. has released new preclinical data on INM-089 further demonstrating promising pharmacological effects targeting dry age-related macular degeneration (AMD). INM-089 is a proprietary small-molecule compound acting as a preferential signaling ligand of cannabinoid CB1 and CB2 receptors.
On the heels of a $4.6 million series A round in December 2023, cell therapy company Rxcell Inc. is planning to raise another $15 million in 2024 to take its iPSC-derived photoreceptors to the clinic for retinitis pigmentosa and other degenerative diseases of the retina.